Wells Fargo & Company Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $900.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective cut by Wells Fargo & Company from $1,050.00 to $900.00 in a report released on Friday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

REGN has been the topic of a number of other research reports. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Citigroup began coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target on the stock. Finally, Bank of America reiterated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,037.33.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $696.88 on Friday. Regeneron Pharmaceuticals has a 12 month low of $691.00 and a 12 month high of $1,211.20. The company has a market cap of $76.58 billion, a P/E ratio of 17.25, a P/E/G ratio of 2.19 and a beta of 0.10. The business’s 50 day moving average is $751.44 and its two-hundred day moving average is $961.06. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals in the third quarter worth about $37,000. Ashton Thomas Private Wealth LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $39,000. Finally, Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.